JERUSALEM (Reuters) -Teva Pharmaceutical Industries reported a slightly larger than expected rise in first-quarter profit, helped by strong sales gains in a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia.

The world's largest generic drugmaker said on Wednesday it earned 52 cents per diluted share, excluding one-time items, in the January-March quarter, up from 48 cents a share a year earlier. Revenue rose 2% to $3.89 billion.

Analysts had forecast earnings of 46 cents per share ex-items for the Israel-based company on revenue of $3.99 billion, LSEG I/B/E/S data showed.

Teva said that confirmed U.S. tariffs were expected to have an immaterial financial impact.